Novel Treatments for Diabetes

Established in 2024 to translate scientific discoveries into treatments for Type 1 Diabetes.

Named after an iconic Australian parrot (Trichoglossus moluccanus) that has an incredible appetite for sweet nectars.

Based in Melbourne, Australia, Lorikeet Therapeutics is working on agonists of the melanocortin 5 receptor to drive insulin independent glucose uptake into skeletal muscle. Reducing the need for people living with Type 1 diabetes to use insulin.